ClinicalTrials.gg
CompletedNCT02571036Updated Dec 13, 2023

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

A Phase 1 interventional study of DCC-2618 and DCC-2618 in Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis and Advanced Cancers, sponsored by Deciphera Pharmaceuticals, LLC. Completed at 26 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
282
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.

Started
2015
the only one that year
Phase 1
3 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is the only one that started in 2015, is one of 3 in phase 1, and was the 1st registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

03

Conditions studied

  • Gastrointestinal Stromal Tumors
  • Advanced Systemic Mastocytosis
  • Advanced Cancers

Keywords

  • Gastrointestinal stromal tumors (GIST)
  • systemic mastocytosis (SM)
  • PDGFR-alpha
  • KIT
  • mast cell leukemia (MCL)
  • mast cell disease (MCD)
  • DCC-2618
  • melanoma
  • aggressive systemic mastocytosis (ASM)
  • soft tissue sarcoma (STS)
  • germ cell tumors
  • penile cancer
  • non-small cell lung carcinoma (NSCLC)
  • renal impairment
  • malignant gliomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Escalation and Expansion Phases)

Patients must meet the following criteria to be eligible to enroll in the study:

  1. Male or female patients ≥18 years of age.
  2. Patients must have confirmed solid tumors or hematologic . Eligible patients include the following:

    1. GIST patients must have a KIT and PDGFRA mutation and must have progressed on or had an intolerability to at least 1 line of systemic anticancer therapy.
    2. SM patients must have a confirmed diagnosis of advanced SM according to 2016 World Health Organization (WHO) criteria for SM and must have documented KIT mutant disease. Patients with imatinib-sensitive KIT mutations must have progressed on or were intolerant to a tyrosine kinase inhibitor. Patients with advanced SM must present with at least 1 eligible C-Finding (organ damage) per 2013 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) \& European Competence Network on Mastocytosis consensus response criteria; please see below for MCL exception.

    Advanced SM includes:

    i. Aggressive SM (ASM)

    ii. SM with associated hematologic neoplasm (SM-AHN), wherein the AHN does not require immediate alternative therapy. AHNs that are eligible include: low grade myelodysplastic syndrome (MDS) with a high SM burden who require treatment for SM only, myeloproliferative neoplasms (MPN), MDS/MPN, unclassifiable MDS, and HES/CEL.

    iii. MCL

    • Patients with histopathologically-confirmed MCL without a C-finding are eligible.

    iv. Symptomatic SSM

    • By definition, SSM patients must have at least 2 B-findings, and symptom burden (eg, flushing, diarrhea, etc.) despite maximal treatment with approved agents to treat mediator symptoms, such as antihistamines and cromolyn sodium.

    v. Patients with hematologic malignancies featuring clonal expansion of eosinophils driven by genomic alterations of KIT or PDGFRA (eg, HES or CEL) are eligible if they have progressed on or are intolerant of imatinib therapy. Patients with de novo imatinib resistant mutations, such as but not limited to KIT D816V or PDGFRA D842V, are eligible without prior imatinib therapy.

    c. Malignant glioma patients with genomic alterations potentially conferring sensitivity to DCC-2618 including, but not limited to, amplification and/or mutations of PDGFRA and/or KIT.

    Other solid tumor patients that have alterations in genes encoding kinases that are targets of DCC-2618. This includes:

    • Melanoma
    • Soft tissue sarcoma patients (including but not limited to: malignant peripheral nerve sheath tumors (MPNST), desmoplastic small round cell tumors (DSRCT), and dermatofibrosarcoma protuberans tumors (DFSP)
    • Other solid tumor patients (non-melanoma, non-STS; specifically germ-cell, penile, and non-small cell lung carcinoma)
    • Renal impairment cohort
  3. (ECOG) performance status (PS) of ≤2.
  4. Adequate organ function and bone marrow function.

Exclusion Criteria (Escalation and Expansion Phases)

Patients meeting any of the following criteria will be excluded from the study:

  1. GIST patients with wild type or unknown KIT or PDGFRA status.
  2. Patients with SM or other hematologic malignancies will be excluded if the following apply:

    1. SM patients with neutropenia accompanied by fever or infection, or thrombocytopenia associated with clinically significant bleeding.

      • Patients with an infection that is well controlled with antibiotics are eligible if there is an immediate need for treatment.
    2. SM-AHN patients diagnosed with:

    i. SM with MDS who require treatment for MDS. ii. Patients requiring immediate treatment for AHN.

    c. Patients with leukemias, with the exception of MCL and CEL, that have progressed after imatinib.

    d. Eosinophilic myeloproliferative neoplasm patients: i. Lacking a mutation that is a known target of DCC-2618.

  3. Prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of DCC-2618. Patients receiving cancer treatment are not eligible if those medications are potentially active against GIST or excluded per protocol.
  4. class III and IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
  5. Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before start of study drug.
  6. Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within the 3 months before start of study drug. Patients with venous thrombotic events ≥3 months before start of study drug on stable anticoagulation therapy are eligible.
  7. Baseline prolongation of the rate- interval based on repeated demonstration of QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT interval corrected (QTc) syndrome.
  8. (LVEF) \<50% or below the lower limit of normal (whichever is higher).
  9. Major surgery within 4 weeks of the first dose of study drug; following major surgeries >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.
  10. Any other clinically significant comorbidities.
  11. Illnesses that could affect oral absorption.
  12. Known or active infection only if the patient is taking per protocol prohibited medications, active , or active hepatitis C infection.
  13. If female, the patient is pregnant or lactating.
  14. Known allergy or to any component of the drug product. Patients with history of Stevens-Johnson syndrome on a prior tyrosine kinase inhibitor (TKI) are excluded.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Escalation

    Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 1

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 2

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 3

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 4

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.\[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 5

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.\[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 6

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 7

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 8

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.\[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 9

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Expansion Cohort 10

    150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. \[Closed for Enrollment\]

    Drug: DCC-2618

  • Experimental
    Extension Cohort

    150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.

    Drug: DCC-2618

Interventions

  • 50 mg formulated tablets

    Also known as: ripretinib

  • 10 mg and 50 mg formulated tablets

    Also known as: ripretinib

06

What researchers measure

Primary outcomes

  1. Safety/tolerability of oral DCC-2618: incidence of adverse events

    Dose limiting toxicities, AEs, SAEs, discontinuation of drug due to toxicity, physical exams and ECOG PS, ophthalmologic examinations, changes from baseline in laboratory parameters, electrocardiograms, LVEF, and vital signs.

    Time frame: Approximately 24 months

  2. Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose

    Time frame: 18 months

  3. Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases

    Objective response rate (ORR); Disease control rate (DCR)

    Time frame: Approximately 24 months

Secondary outcomes

  1. Determine the PK profile of oral DCC-2618

    Time frame: Predose and up to 24 hours postdose (Cycle = 28 Days)

  2. Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies

    Objective response rate (ORR); Disease control rate (DCR)

    Time frame: Approximately 24 months

07

Study locations

26 sites
  • Honor Health (GIST, mastocytosis, other solid tumors)
    Scottsdale, Arizona 85258, United States
  • UCLA Hematology Center (mastocytosis)
    Los Angeles, California 90024, United States
  • UCLA (glial malignancies only)
    Los Angeles, California 90095, United States
  • Stanford University Comprehensive Cancer Center (GIST)
    Palo Alto, California 94304, United States
  • Stanford University Hematology Clinic (mastocytosis)
    Palo Alto, California 94305, United States
  • UCSF (glial malignancies only)
    San Francisco, California 94143, United States
  • Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)
    Jacksonville, Florida 32224, United States
  • University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)
    Miami, Florida 33136, United States
  • Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
    Boston, Massachusetts 02215, United States
  • Colombia University Medical Center (mastocytosis)
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
    New York, New York 10065, United States
  • OHSU (GIST & mastocytosis only)
    Portland, Oregon 97239, United States
  • Fox Chase Cancer Center (GIST only)
    Philadelphia, Pennsylvania 19111, United States
  • MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
    Salt Lake City, Utah 84103, United States
  • Virginia Commonwealth University School of Medicine (mastocytosis)
    Richmond, Virginia 23219, United States
  • Princess Margaret Cancer Centre (GIST, other solid tumors)
    Toronto, M5G IX5, Canada
  • Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)
    Aachen, 52074, Germany
  • HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)
    Berlin, 13125, Germany
  • Essen University Hospital (mastocytosis, GIST, and other solid tumors)
    Essen, 45147, Germany
  • Freiburg University Hospital (mastocytosis, and other solid tumors)
    Freiburg, 79106, Germany
  • University Medical Centre Mannheim (mastocytosis)
    Mannheim, 68167, Germany
  • University Hospital of Verona (mastocytosis)
    Verona, 37134, Italy
  • Leiden University Medical Center (GIST and other solid tumors)
    Leiden, 2333, Netherlands
  • Guy's Hospital (mastocytosis only)
    London, SE1 9RT, United Kingdom
  • Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)
    London, SW3 6JJ, United Kingdom
08

References and documents

Publications

  • Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 Oct 1;38(28):3294-3303. doi: 10.1200/JCO.20.00522. Epub 2020 Aug 17. PubMed 32804590 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2022, 77 months.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Oct 8, 2015
StartActual
Nov 2015
Primary completionActual
Apr 29, 2022
CompletionActual
Apr 29, 2022
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02571036
Responsible party
Sponsor
First posted
Oct 8, 2015
Start date
Nov 2015
Primary completion
Apr 29, 2022
Completion
Apr 29, 2022
Last update
Dec 13, 2023

Study contacts

Deciphera Pharmaceuticals, LLC
study director · Deciphera Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ripretinib

Start the discussion